Biotechnology, while hurting along with the rest of the market, is one of the few that can boast market outperformance during these tough market times, evidenced in the performance of the related exchange traded funds (ETFs).
Billy Fisher for TheStreet points out that while the S&P 500 has lost 35% year-to-date, biotech funds have had stand-out performances even though resistance has been a factor.
Biotech HOLDRs (BBH) has done especially well, as it is the only biotech ETF in positive territory year-to-date, up 5.1%.
